Galectin-3 Biomarker Data for Cognitive Impairment: A Systematic Review and Meta-Analysis

A systematic review and meta-analysis document summarizing evidence on the biomarker Galectin-3 in cognitive impairment. The document includes results from nine studies comprising 877 patients with cognitive impairment and 715 healthy controls, authored by Ying-ying Yang and last updated in May 2026. It reports combined effect sizes, subgroup analyses for vascular risk factors and disease types, and assesses study heterogeneity and publication bias.

Use Cases

• Training predictive models for cognitive impairment risk based on biomarker levels mentioned in the meta-analysis.
• Validating the association between Galectin-3 and specific cognitive impairment subtypes like Mild Cognitive Impairment (MCI).
• Conducting secondary meta-analyses on neuroinflammatory biomarkers using the reported effect sizes and confidence intervals.
• Designing clinical studies for early detection of cognitive impairment with vascular risk factors.

Strengths

• The meta-analysis is based on data from nine studies and 1,592 total participants (877 patients, 715 controls).
• Results include specific statistical measures like Weighted Mean Difference (WMD) and 95% confidence intervals for the main finding.
• Subgroup analyses are provided for patients with vascular risk factors and specific disease types (MCI vs. Alzheimer's Disease).

Limitations

• The dataset is a 17.2 KB document summary; the underlying primary study data is not included.
• Row count and column-level documentation for any potential underlying data are unknown.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of seven databases up to March 8, 2026.

Time Range

Studies included from database establishment until March 8, 2026.

Freshness

Last updated 2026-05-25 04:32:51; freshness should be verified.